Viral vectors as vaccine carriers.
This chapter reviews the performance of viral vectors based on adenoviruses or adeno-associated virus as vaccine carriers for infectious diseases. Replication-defective adenovirus vectors based on multiple human or non-human serotypes have consistently induced potent transgene product-specific B and T cell responses and are increasingly being explored in human clinical trials. The immunogenicity of most vectors based on adeno-associated virus vectors has been poor with the exception of a recently described hybrid vector from rhesus macaques that due to its ability to induce potent responses in mice warrant further investigation.
Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, United States. Electronic address: ertl@wistar.upenn.edu.
Hildegund Cj
HC
Ertl
D056704:Adaptive Immunity; D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D000229:Dependovirus / Q000235:genetics*; D004337:Drug Carriers; D005822:Genetic Vectors; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics* / Q000276:immunology*
D004337:Drug Carriers; D014614:Vaccines, Synthetic